Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
Dr. Dereck Mush, MD, MBA
Generate Biomedicines
Applies generative machine learning to invent novel proteins and therapeutics based on biological principles.
Generate Biomedicines is known for applies generative machine learning to invent novel proteins and therapeutics based on biological principles. It is based in Somerville, United States, is at the Series C+ stage with $740M raised, and sits in our Biotech & Pharma category.
What they do
The company uses generative artificial intelligence models to predict protein structures and design custom therapeutics. Biotech and pharmaceutical companies utilize its platform to engineer novel enzymes, antibodies, and proteins to address previously untreatable medical conditions.
The record
- Vertical
- Biotech & Pharma
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Series C+
- Headquarters
- Somerville, United States
- Region
- North America
- Founded
- 2018
- Total funding
- $740M raised
Notable investors: Flagship Pioneering, Fidelity Management, T. Rowe Price, ARCH Venture Partners.
Also in Biotech & Pharma
More in Biotech & Pharma: Biotech & Pharma startups/HealthTech startup database
Related on The Signal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBA
Renting the Molecule Factory: Pierre Fabre, XtalPi and Mid-Sized Pharma's AI Bet
Dr. Dereck Mush, MD, MBA